Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | MLYCD | O95822 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311171 | 0.90 | RXFP1 (0.61) | SMN1; SMN2KMT2AKDM4EMAPTHPGD | |
| SCHEMBL21311149 | 0.84 | ALDH1A1 (0.63) | KMT2AKDM4EMAPTHPGDRXFP1 | |
| SCHEMBL21311316 | 0.84 | RXFP1 (0.56) | SMN1; SMN2KMT2AKDM4EMAPTHPGD | |
| SCHEMBL17554030 | 0.79 | NR1H4 (0.62) | RXFP1PTGS1NR1H4PPARGPPARD | |
| SCHEMBL1918788 | 0.78 | KDM4E (0.64) | SMN1; SMN2KMT2AKDM4EMAPTHPGD | |
| SCHEMBL28431283 | 0.78 | PTGS1 (0.61) | TSHRRXFP1PTGS1NR1H4PPARG | |
| SCHEMBL15775396 | 0.77 | PTGS1 (0.68) | RXFP1PTGS1NR1H4PPARGPPARD | |
| SCHEMBL19348446 | 0.76 | BCL3 (0.60) | TSHRRXFP1NR1H4ALDH1A1 | |
| SCHEMBL21311176 | 0.76 | PTGS1 (0.62) | KMT2AKDM4EMAPTRXFP1PTGS1 | |
| SCHEMBL17847349 | 0.76 | GAA (0.58) | SMN1; SMN2KMT2AKDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
| WO-2018075947-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | SMN1; SMN2 959/4885KMT2A 2961/4885KDM4E 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.